Home > Boards > US Listed > Biotechs > Acadia Pharmaceuticals Inc. (ACAD)

Let's trigger those stop losses at $15.68...

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
gi197845 Member Profile
 
Followed By 4
Posts 2,661
Boards Moderated 1
Alias Born 08/16/16
160x600 placeholder
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021 Business Wire - 10/27/2021 9:00:00 AM
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference Business Wire - 10/25/2021 9:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/19/2021 5:32:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/19/2021 5:31:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/1/2021 5:34:13 PM
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire - 9/2/2021 9:00:00 AM
Acadia Pharmaceuticals Announces Executive Leadership Change Business Wire - 9/1/2021 4:05:00 PM
Dermata therapeutics appoints Kyri Van Hoose as CFO Seeking Alpha - 9/1/2021 6:55:32 AM
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021 Business Wire - 8/5/2021 4:05:00 PM
DRP Treatment’s Path Ahead Unclear, yet Current Risk/Reward Appears Favorable TipRanks - 8/5/2021 10:55:30 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2021 6:03:49 AM
ACADIA Pharma slides after 2021 guidance lagged expectations Seeking Alpha - 8/4/2021 5:03:42 PM
ACADIA Pharma EPS beats by $0.03, misses on revenue; FY21 guidance lowered Seeking Alpha - 8/4/2021 4:22:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2021 4:17:05 PM
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results Business Wire - 8/4/2021 4:05:00 PM
The Street’s Gaze Turns to FDA Meeting’s Outcome on DRP Treatment TipRanks - 8/3/2021 7:30:30 PM
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis Business Wire - 7/21/2021 5:05:00 PM
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Asso... Business Wire - 7/14/2021 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/24/2021 5:02:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2021 4:43:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2021 4:42:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2021 4:41:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2021 4:40:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2021 4:39:45 PM
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders Business Wire - 6/3/2021 11:26:00 AM
gi197845   Monday, 08/16/21 03:22:59 PM
Re: None
Post # of 3045 
Let's trigger those stop losses at $15.68...

BTW, Steve Davis wore an unbuttoned too low shirt during the Cancord conference call, when he should have worn a suit...

He stuttered often...and the words "Um and Ah" were used most often...

He also clicked the presentation clicker, way too loudly...

He didn't let the women speak...

Optics matter!

What a diarrhea joke!

















Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences